Method of reducing craving in mammals

Abstract

A method of reducing cravings in a mammal to food or an addictive substance is disclosed. The method comprises administering to the mammal an effective amount of a D 1 /D 5 antagonist or a D 1 /D 5 partial agonist alone or in combination with other specified CNS compounds.

What is claimed is:  
     
         1 . A method for reducing cravings to food or an addictive substance in a mammal comprising administering to the mammal an anti-craving effective amount of a D 1 /D 5  antagonist, a D 1 /D 5  partial agonist or mixtures thereof.  
     
     
         2 . The method of    claim 1    wherein the D 1 /D 5  antagonist or D 1 /D 5  partial agonist is administered at a daily dosage range of about 0.01 to about 500 mg/kg.  
     
     
         3 . The method of    claim 2    wherein the D1/D5 antagonist is administered at a daily dosage range of about 1 to about 150 mg/kg.  
     
     
         4 . The method of    claim 2    wherein the addictive substance is cocaine, amphetamine, nicotine, opiates, tobacco or alcohol.  
     
     
         5 . The method of    claim 4    wherein the D 1 /D 5  antagonist is selected from the class consisting of SCH39166, SCH23390, BTS-73-947, NNC-22-0010, JHS-271, JHS-198, JHS-136 and A69024, and the D 1 /D 5  partial agonist is SKF 38393.  
     
     
         6 . The method of    claim 5    wherein the D 1 /D 5  antagonist is SCH 39166.  
     
     
         7 . The method of    claim 6    wherein the substance craved is food.  
     
     
         8 . The method of    claim 7    further comprising the administration of a compound selected from the class consisting of sibutramine, fluoxitine, fenfluramine and analogs, amphetamine and analogs, phenteramine, diethylproprion and mazindol.  
     
     
         9 . The method of    claim 6    wherein the substance craved is nicotine.  
     
     
         10 . The method of    claim 9    further comprising the administration of a compound selected from the class consisting of buspirone and buproprion.  
     
     
         11 . The method of    claim 6    wherein the substance craved is alcohol.  
     
     
         12 . The method of    claim 11    further comprising the administration of a compound selected from the class consisting of disulfiram, acamprosate and naltrexone.  
     
     
         13 . A method for reducing cravings to food or an addictive substance in a mammal comprising administering to the mammal an anti-craving effective amount of a compound selected from a D 1 /D 5  antagonist, a D 1 /D 5  partial agonist and mixtures thereof, and a compound selected from the class consisting of: 
 A. anti-obesity compounds;    B. serotonin receptor agonists and antagonists;    C. antipsychotics/anxiolytics;    D. antidepressants;    E. dopaminergic agonists;    F. anticonvulsants/mood stimulants;    G. cocaine-like agonists;    H. cocaine catalytic antibodies; and    I. alcohol antagonist drugs.    
     
     
         14 . The method of    claim 13    wherein the D 1 /D 5  antagonist is selected from the class consisting of SCH39166, SCH23390, BTS-73-947, NNC-22-0010, JHS-271, JHS-198, JHS-136 and A-69024.  
     
     
         15 . The method of    claim 14    wherein the D 1 /D 5  antagonist is SCH39166.  
     
     
         16 . A method for reducing food cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166.  
     
     
         17 . A method for reducing nicotine cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166.  
     
     
         18 . A method for reducing alcohol cravings in a mammal comprising administering to the mammal an anti-craving effective amount of SCH 39166  
     
     
         19 . A kit to reduce cravings to food or an addictive substance comprising a compound selected from the class consisting of a D 1 /D 5  antagonist, a D 1 /D 5 partial agonist and mixtures thereof in combination with one or more compounds selected from the class consisting of: 
 A. anti-obesity compounds;    B. serotonin receptor agonists and antagonists;    C. antipsychotics/anxiolytics;    D. antidepressants;    E. dopaminergic agonists;    F. anticonvulsants/mood stimulants;    G. cocaine-like agonists;    H. cocaine catalytic antibodies; and    I. alcohol antagonist drugs.    
     
     
         20 . The kit of    claim 19    wherein the D 1 /D 5  antagonist is SCH39166.